Ralston D R, St John R C
Division of Pulmonary and Critical Care Medicine, Ohio State University Medical Center, Columbus, USA.
Clin Chest Med. 1996 Jun;17(2):307-17. doi: 10.1016/s0272-5231(05)70316-6.
In recent years, an improved understanding of the pathogenesis of sepsis, along with an explosion in the biotechnology industry, has led to the development of a variety of agents with potential to interdict the pathogenesis of sepsis at many points. This article reviews the rationale, efficacy and shortcomings of these immunotherapeutic agents as they relate to the management of human septic shock.
近年来，随着对脓毒症发病机制的认识不断加深，以及生物技术产业的蓬勃发展，已研发出多种有可能在多个环节阻断脓毒症发病机制的药物。本文综述了这些免疫治疗药物在治疗人类感染性休克方面的基本原理、疗效及不足之处。
